Rhinomed Limited
RHNMF · OTC
12/30/2023 | 6/30/2023 | 12/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $8,000 | $4,089 | $3,384 | $5,659 |
| % Growth | 95.7% | 20.8% | -40.2% | – |
| Cost of Goods Sold | $0 | $3,728 | $3,935 | $1,563 |
| Gross Profit | $8,000 | $360 | -$551 | $4,096 |
| % Margin | 100% | 8.8% | -16.3% | 72.4% |
| R&D Expenses | $0 | $698 | $463 | $1,154 |
| G&A Expenses | $0 | $309 | $345 | $376 |
| SG&A Expenses | $0 | $3,241 | $3,682 | $4,762 |
| Sales & Mktg Exp. | $0 | $1,311 | $1,496 | $2,688 |
| Other Operating Expenses | $0 | $1,265 | $0 | $0 |
| Operating Expenses | $0 | $5,204 | $4,145 | $6,119 |
| Operating Income | $8,000 | -$4,844 | -$4,696 | -$2,561 |
| % Margin | 100% | -118.5% | -138.8% | -45.3% |
| Other Income/Exp. Net | $0 | -$1,622 | -$287 | $530 |
| Pre-Tax Income | $0 | -$6,466 | -$4,983 | -$2,031 |
| Tax Expense | $0 | -$212 | -$329 | $0 |
| Net Income | $0 | -$6,254 | -$4,654 | -$2,031 |
| % Margin | 0% | -153% | -137.6% | -35.9% |
| EPS | 0 | -0.022 | -0.016 | -0.008 |
| % Growth | 100% | -34.4% | -114.5% | – |
| EPS Diluted | 0 | -0.022 | -0.016 | -0.008 |
| Weighted Avg Shares Out | 285,720 | 285,617 | 285,546 | 268,879 |
| Weighted Avg Shares Out Dil | 285,720 | 285,720 | 285,720 | 269,412 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $2 | $0 | $8 |
| Interest Expense | $0 | $242 | $70 | $0 |
| Depreciation & Amortization | $0 | $44 | $122 | $54 |
| EBITDA | $8,000 | -$4,441 | -$4,207 | -$2,279 |
| % Margin | 100% | -108.6% | -124.3% | -40.3% |